Gilead Sciences (GILD): Investors Are Undervaluing The Pipeline - Leerink
Get Alerts GILD Hot Sheet
Rating Summary:
24 Buy, 16 Hold, 2 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Leerink Partners analyst, Geoffrey Porges, noted that his positive view on Gilead Sciences (NASDAQ: GILD) includes the optionality of its pipeline (an aspect of the company generally overlooked by investors) in addition to its dominant HIV and HCV franchises. This pipeline includes GS-5745, an anti-MMP9 (matrix metalloproteinase 9) antibody, currently in development for a wide-range of indications, including gastric cancer (GC), ulcerative colitis (UC), cystic fibrosis (CF), Crohn’s Disease (CD), chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis (RA). Inhibitors of the MMP class have had a poor history, with nearly 50 different molecules failing in development. Investors could be forgiven for being circumspect about the potential of GS-5745. Following the presentation of intriguing phase I data in gastric cancer at 2016’s ASCO, along with the recent publication of favorable phase I UC data, he has reviewed the potential of GS-5745 with four MEDACorp specialists with long experience in the discovery and development of MMP inhibitors and modulators. Overall, while these KOLs were intrigued by GS-5745’s mechanism of action and the preliminary data, they were very hesitant to raise expectations about the prospects for this drug. With scientific evidence supporting a more prominent role for MMP9 in inflammation compared to oncology.
No change to the Outperform rating or price target of $120.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $82.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Expands Indication for Gilead's (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
- 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
- Hyundai Motor (005380:KS) (HYMTF) PT Raised to KRW290 at Citi
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!